About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Cebpatm1Gonz
targeted mutation 1, Frank Gonzalez
MGI:2177133
Summary 10 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Cebpatm1Gonz/Cebpatm1Gonz
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-cre)1Jaw/0
involves: 129 * 129X1/SvJ * C57BL/6 * FVB/N MGI:3809493
cn2
Cebpatm1Gonz/Cebpatm9Nerl
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(KRT14-cre)1Cgn/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2 MGI:4366856
cn3
Cebpatm1Gonz/Cebpatm1Gonz
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(KRT14-cre)1Cgn/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2 MGI:4366857
cn4
Cebpatm1Gonz/Cebpa+
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(KRT14-cre)1Cgn/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2 MGI:4366854
cn5
Cebpatm1Gonz/Cebpatm2Nerl
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(KRT14-cre)1Cgn/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2 MGI:4366855
cn6
Cebpatm1Gonz/Cebpatm1Gonz
Cebpbtm1Es/Cebpbtm1Es
Tg(KRT14-cre/ERT)20Efu/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 MGI:5645076
cn7
Cebpatm1Gonz/Cebpatm1Gonz
Tg(KRT14-cre/ERT)20Efu/0
involves: 129X1/SvJ * C57BL/6 * CD-1 MGI:5645058
cn8
Cebpatm1Gonz/Cebpatm1Gonz
Tg(KRT5-cre)5132Jlj/0
involves: 129X1/SvJ * C57BL/6 * DBA/2J MGI:3809494
cn9
Cebpatm1Gonz/Cebpatm1Gonz
Lepob/Lepob
Tg(Alb1-cre)1Dlr/0
involves: 129X1/SvJ * C57BL/6J * FVB/N MGI:3809489
cn10
Cebpatm1Gonz/Cebpatm1Gonz
Tg(Alb1-cre)1Dlr/0
involves: 129X1/SvJ * FVB/N MGI:3809490


Genotype
MGI:3809493
cn1
Allelic
Composition
Cebpatm1Gonz/Cebpatm1Gonz
Tg(SFTPC-rtTA)5Jaw/0
Tg(tetO-cre)1Jaw/0
Genetic
Background
involves: 129 * 129X1/SvJ * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cebpatm1Gonz mutation (1 available); any Cebpa mutation (19 available)
Tg(SFTPC-rtTA)5Jaw mutation (4 available)
Tg(tetO-cre)1Jaw mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice die within 2 to 3 hours of birth

respiratory system
• capillary beds in lungs are immature
• however, vascular smooth muscle development is normal
• at birth, mice exhibit pulmonary congestion
• between E16.5 and E18.5, mice exhibit reduced dilation of the saccules, thick mesenchyme and a lack of squamous type I cells unlike in wild-type mice
• type I cell maturation is disrupted
• mature type I cells are absent
• type II cell maturation is disrupted and cells lack stored pulmonary surfactant
• at birth
• mice produce less surfactant protein than wild-type mice

cardiovascular system
• capillary beds in lungs are immature
• however, vascular smooth muscle development is normal
• at birth, mice exhibit pulmonary congestion




Genotype
MGI:4366856
cn2
Allelic
Composition
Cebpatm1Gonz/Cebpatm9Nerl
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(KRT14-cre)1Cgn/0
Genetic
Background
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cebpatm1Gonz mutation (1 available); any Cebpa mutation (19 available)
Cebpatm9Nerl mutation (0 available); any Cebpa mutation (19 available)
Cebpbtm1Nerl mutation (0 available); any Cebpb mutation (26 available)
Tg(KRT14-cre)1Cgn mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype



Genotype
MGI:4366857
cn3
Allelic
Composition
Cebpatm1Gonz/Cebpatm1Gonz
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(KRT14-cre)1Cgn/0
Genetic
Background
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cebpatm1Gonz mutation (1 available); any Cebpa mutation (19 available)
Cebpbtm1Nerl mutation (0 available); any Cebpb mutation (26 available)
Tg(KRT14-cre)1Cgn mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice die within 5 to 8 hours of birth

growth/size/body
• at birth mice loss weight rapidly likely due to severe transepithelial water loss without lipophilic barrier dysfunction

vision/eye

integument
• the interfollicular epidermis exhibits an immature phenotype with fewer and smaller keratohyalin granules in the stratum granulosum and immature non-scaling stratum corneum and parakeratosis compared with wild-type mice

cellular




Genotype
MGI:4366854
cn4
Allelic
Composition
Cebpatm1Gonz/Cebpa+
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(KRT14-cre)1Cgn/0
Genetic
Background
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cebpatm1Gonz mutation (1 available); any Cebpa mutation (19 available)
Cebpbtm1Nerl mutation (0 available); any Cebpb mutation (26 available)
Tg(KRT14-cre)1Cgn mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
integument
N
• mice have normal epidermis




Genotype
MGI:4366855
cn5
Allelic
Composition
Cebpatm1Gonz/Cebpatm2Nerl
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(KRT14-cre)1Cgn/0
Genetic
Background
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cebpatm1Gonz mutation (1 available); any Cebpa mutation (19 available)
Cebpatm2Nerl mutation (0 available); any Cebpa mutation (19 available)
Cebpbtm1Nerl mutation (0 available); any Cebpb mutation (26 available)
Tg(KRT14-cre)1Cgn mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype



Genotype
MGI:5645076
cn6
Allelic
Composition
Cebpatm1Gonz/Cebpatm1Gonz
Cebpbtm1Es/Cebpbtm1Es
Tg(KRT14-cre/ERT)20Efu/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cebpatm1Gonz mutation (1 available); any Cebpa mutation (19 available)
Cebpbtm1Es mutation (2 available); any Cebpb mutation (26 available)
Tg(KRT14-cre/ERT)20Efu mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• 4OHT-treated mutant mice show molecular changes in K5, K14, K1, and K10 that are consistent with a defect in the basal to spinous keratinocyte transition
• 4OHT-treated mutant mice show a significant increase in the numbers of BrdU positive S-phase cells in the IFE and ORS keratinocytes relative to controls
• a 4.7-fold increase is noted in BrdU positive basal S-phase keratinocytes
• a ~27-fold increase is noted in in BrdU positive suprabasal S-phase keratinocytes

endocrine/exocrine glands
• in 4OHT-treated mutant mice, sebaceous glands contain abnormal looking sebocytes that appear undifferentiated, show reduced cytoplasmic volume, and lack clear fine vacuolation supportive of lipid accumulation
• affected glands show increased cellular density with more closely apposed nuclei and the cells are morphologically similar to reserve undifferentiated cells
• 4OHT-treated mutant mice show marked atrophy of preputial gland lobules and reduced numbers of clear finely vacuolated sebocytes
• in 4OHT-treated mutant mice, sebaceous glands contain abnormal looking sebocytes that appear undifferentiated
• 4OHT-treated mutant mice exhibit loss of morphologically distinct differentiated sebocytes in the sebaceous, Meibomian, and preputial glands
• in 4OHT-treated mutant mice, sebaceous gland lobules associated with hair follicles fail to stain with Oil Red O indicating the absence of sebum and terminally differentiated sebocytes
• sebocyte differentiation is blocked as determined by reduced expression of stearoyl-CoA desaturase and melanocortin 5 receptor, two markers of terminal sebocyte differentiation
• 4OHT-treated mutant mice display hyperplasia of the Meibomian ducts
• 4OHT-treated mutant mice display atrophic Meibomian glands with greatly reduced lobule size and reduced numbers of differentiated sebocytes with clear vacuolated cytoplasm
• 4OHT-treated mutant mice exhibit lack of sebum production

integument
• 4OHT-treated mutant mice show a significant increase in the numbers of BrdU positive S-phase cells in the IFE and ORS keratinocytes relative to controls
• a 4.7-fold increase is noted in BrdU positive basal S-phase keratinocytes
• a ~27-fold increase is noted in in BrdU positive suprabasal S-phase keratinocytes
• in 4OHT-treated mutant mice, sebaceous glands contain abnormal looking sebocytes that appear undifferentiated, show reduced cytoplasmic volume, and lack clear fine vacuolation supportive of lipid accumulation
• affected glands show increased cellular density with more closely apposed nuclei and the cells are morphologically similar to reserve undifferentiated cells
• 4OHT-treated mutant mice show marked atrophy of preputial gland lobules and reduced numbers of clear finely vacuolated sebocytes
• in 4OHT-treated mutant mice, sebaceous glands contain abnormal looking sebocytes that appear undifferentiated
• 4OHT-treated mutant mice exhibit loss of morphologically distinct differentiated sebocytes in the sebaceous, Meibomian, and preputial glands
• in 4OHT-treated mutant mice, sebaceous gland lobules associated with hair follicles fail to stain with Oil Red O indicating the absence of sebum and terminally differentiated sebocytes
• sebocyte differentiation is blocked as determined by reduced expression of stearoyl-CoA desaturase and melanocortin 5 receptor, two markers of terminal sebocyte differentiation
• 4OHT-treated mutant mice display hyperplasia of the Meibomian ducts
• 4OHT-treated mutant mice display atrophic Meibomian glands with greatly reduced lobule size and reduced numbers of differentiated sebocytes with clear vacuolated cytoplasm
• 4OHT-treated mutant mice exhibit lack of sebum production
• 4OHT-treated mutant mice display focal and regional areas of moderate to severe hyperplasia of the follicular infundibular epithelium and the infundibular outer root sheath (ORS) keratinocytes
• 4OHT-treated mutant mice display hyperplasia of the infundibular outer root sheath (ORS) keratinocytes
• 4OHT-treated mutant mice show defects in epidermal stratified squamous differentiation
• 4OHT-treated mutant mice show molecular changes in K5, K14, K1, and K10 that are consistent with a defect in the basal to spinous keratinocyte transition
• 4OHT-treated mutant mice display a dysplastic, disorganized basal layer with highly abnormal variations in cell and nucleus size
• a 4.7-fold increase is noted in BrdU positive basal S-phase keratinocytes relative to controls
• 4OHT-treated mutant mice display a significantly thickened stratum corneum
• 4OHT-treated mutant mice display low levels of parakeratosis
• 4OHT-treated mutant mice display a dysplastic, disorganized spinous layer with highly abnormal variations in cell and nucleus size
• K10, an early marker of the spinous layer and of the basal to spinous transition is significantly reduced
• K1, another early marker of the spinous layer, is delayed in its expression and instead of being expressed in the layer adjacent to the basal cell layer, K1 is not expressed until ~2-3 layers of cells above the basal layers
• a ~27-fold increase is noted in in BrdU positive suprabasal S-phase keratinocytes relative to controls
• 4OHT-treated mutant mice display hyperplasia of the interfollicular epidemis (IFE) with a significant increase in the number of nucleated epidermal cell layers; focal areas of hyperplasia are detected as early as 4 days and become more extensive and severe at 8, 12, and 18 days after start of 4OHT treatment
• severe regional epidermal hyperplasia of the haired skin eyelid epidermis is observed

renal/urinary system
• 4OHT-treated mutant mice show marked atrophy of preputial gland lobules and reduced numbers of clear finely vacuolated sebocytes

reproductive system
• 4OHT-treated mutant mice show marked atrophy of preputial gland lobules and reduced numbers of clear finely vacuolated sebocytes

vision/eye
• 4OHT-treated mutant mice exhibit dry, swollen, and partially closed eyes
• 4OHT-treated mutant mice display hyperplasia of the Meibomian ducts
• 4OHT-treated mutant mice display atrophic Meibomian glands with greatly reduced lobule size and reduced numbers of differentiated sebocytes with clear vacuolated cytoplasm




Genotype
MGI:5645058
cn7
Allelic
Composition
Cebpatm1Gonz/Cebpatm1Gonz
Tg(KRT14-cre/ERT)20Efu/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cebpatm1Gonz mutation (1 available); any Cebpa mutation (19 available)
Tg(KRT14-cre/ERT)20Efu mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• 4OHT-treated mutant mice show a significant increase in the number of BrdU positive basal keratinocytes relative to controls

integument
N
• 4OHT-treated mutant mice show no major changes in the morphology of interfollicular epidemis, outer root sheath of the hair follicle, and sebaceous glands relative to controls
• normal IHC staining for K5, K10, loricrin and involucrin is observed in epidermis
• 4OHT-treated mutant mice show a significant increase in the number of BrdU positive basal keratinocytes relative to controls
• 4OHT-treated mutant mice show a significant increase in the number of nucleated cell layers relative to controls
• 4OHT-treated mutant mice show a moderate increase in epidermal thickness relative to controls




Genotype
MGI:3809494
cn8
Allelic
Composition
Cebpatm1Gonz/Cebpatm1Gonz
Tg(KRT5-cre)5132Jlj/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6 * DBA/2J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cebpatm1Gonz mutation (1 available); any Cebpa mutation (19 available)
Tg(KRT5-cre)5132Jlj mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• mice exhibit increased susceptibility to skin tumors induced by DMBA and TPA treatment compared to similarly treated wild-type mice
• pre-alignant tumors induced by DMBA and TPS exhibit increased growth rate compared to in similarly treated wild-type mice
• DMBA and TPA induced tumors exhibit earlier onset, faster progression to malignancy and increased volume compared to in tumors induced in wild-type mice
• tumors induced by DMBA and TPA treatment
• DMBA and TPA induced tumors exhibit earlier onset, faster progression to malignancy and increased volume compared to in tumors induced in wild-type mice
• 2 of 13 mice develop squamous cell carcinomas following treatment with DBMA and TPA unlike in wild-type mice
• DMBA and TPA induced tumors progress to malignant squamous cell carcinoma unlike in wild-type cells

integument
N
• epidermal homeostasis is normal
• mice exhibit increased susceptibility to skin tumors induced by DMBA and TPA treatment compared to similarly treated wild-type mice
• pre-alignant tumors induced by DMBA and TPS exhibit increased growth rate compared to in similarly treated wild-type mice
• DMBA and TPA induced tumors exhibit earlier onset, faster progression to malignancy and increased volume compared to in tumors induced in wild-type mice
• tumors induced by DMBA and TPA treatment




Genotype
MGI:3809489
cn9
Allelic
Composition
Cebpatm1Gonz/Cebpatm1Gonz
Lepob/Lepob
Tg(Alb1-cre)1Dlr/0
Genetic
Background
involves: 129X1/SvJ * C57BL/6J * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cebpatm1Gonz mutation (1 available); any Cebpa mutation (19 available)
Lepob mutation (5 available); any Lep mutation (21 available)
Tg(Alb1-cre)1Dlr mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
adipose tissue
• adipocytes are smaller than in Cebpatm1Gonz Lepob homozygotes

homeostasis/metabolism
• compared to in similarly treated Cebpatm1Gonz Lepob homozygotes when fed a high carbohydrate diet
• when fed a high carbohydrate diet, mice exhibit elevated serum glucose levels compared to similarly treated Cebpatm1Gonz Lepob homozygotes
• compared to in similarly treated Cebpatm1Gonz Lepob homozygotes when fed regular chow
• compared to in similarly treated Cebpatm1Gonz Lepob homozygotes when fed regular chow
• hepatic glycogen content is higher than in Cebpatm1Gonz Lepob homozygotes
• compared to similarly treated Cebpatm1Gonz Lepob homozygotes when fed regular chow
• expression of genes involved in lipogenesis are decreased compared to in Cebpatm1Gonz Lepob homozygotes
• when fed a high carbohydrate diet, mice exhibit a slight increase in serum VLDL compared to in similarly treated Cebpatm1Gonz Lepob homozygotes
• compared to in similarly treated Cebpatm1Gonz Lepob homozygotes when fed regular chow
• compared to in similarly treated Cebpatm1Gonz Lepob homozygotes when fed a high carbohydrate diet
• compared to in similarly treated Cebpatm1Gonz Lepob homozygotes when fed a high carbohydrate diet
• compared to in similarly treated Cebpatm1Gonz Lepob homozygotes when fed regular chow
• when fed a high carbohydrate diet, mice exhibit a 47% lower hepatic cholesterol level compared to Cebpatm1Gonz Lepob homozygotes
• hepatic triglyceride levels are lower than in Cebpatm1Gonz Lepob homozygotes
• when fed a high carbohydrate diet, mice exhibit a 46% lower hepatic triglyceride level compared to Cebpatm1Gonz Lepob homozygotes

liver/biliary system
• hepatic glycogen content is higher than in Cebpatm1Gonz Lepob homozygotes
• when fed a high carbohydrate diet, mice exhibit a 47% lower hepatic cholesterol level compared to Cebpatm1Gonz Lepob homozygotes
• hepatic triglyceride levels are lower than in Cebpatm1Gonz Lepob homozygotes
• when fed a high carbohydrate diet, mice exhibit a 46% lower hepatic triglyceride level compared to Cebpatm1Gonz Lepob homozygotes
• mice are resistant to high carbohydrate diet induced steatosis

growth/size/body
• compared to in similarly treated Cebpatm1Gonz Lepob homozygotes when fed a high carbohydrate diet




Genotype
MGI:3809490
cn10
Allelic
Composition
Cebpatm1Gonz/Cebpatm1Gonz
Tg(Alb1-cre)1Dlr/0
Genetic
Background
involves: 129X1/SvJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cebpatm1Gonz mutation (1 available); any Cebpa mutation (19 available)
Tg(Alb1-cre)1Dlr mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• when fed normal chow or a high carbohydrate diet





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory